More about

Adalimumab

News
August 20, 2024
2 min read
Save

Biosimilars, originators discontinued at similar rates for inefficacy, adverse events

Subcutaneous TNF inhibitors and their biosimilars are discontinued due to inefficacy and adverse events at similar rates in patients with rheumatic diseases, according to data from Spain published in The Journal of Rheumatology.

News
August 08, 2024
2 min read
Save

Biosimilars cost effective vs. leflunomide in rheumatoid arthritis

In patients with rheumatoid arthritis who have an inadequate response to methotrexate, a treatment sequence beginning with a biosimilar appeared cost-effective compared with leflunomide, according to data published in JAMA Network Open.

News
June 27, 2024
10 min listen
Save

Healio Minute Podcast, Rheumatology/Psoriatic Arthritis Edition: Top Headlines - Week of June 24, 2024

In this edition, extensive psoriasis and IBD history predict difficult-to-treat psoriatic arthritis, targeted therapies demonstrate low risk for serious infection and more.

News
June 06, 2024
2 min read
Save

Targeted psoriatic arthritis therapies demonstrate low risk for serious infection

Serious infections were uncommon among patients with psoriatic arthritis exposed to targeted therapies for the first time in “a large and exhaustive” French cohort, according to data published in RMD Open.

News
June 01, 2024
8 min watch
Save

VIDEO: Recent advancements in rheumatoid arthritis

In this video, Maria Danila, MD, discusses recent advancements in rheumatoid arthritis.

News
May 24, 2024
4 min read
Save

IL-17 inhibitors may break TNFi ‘glass ceiling’ in psoriatic arthritis prescribing

Although TNF inhibitors remain the first choice biologic for many rheumatologists treating psoriatic arthritis, interleukin-17 inhibitors may soon overtake them, according to a market analysis from Spherix Global Insights.

News
May 08, 2024
3 min read
Save

Low anti-TNF concentrations at week 14 linked to long-term loss of response in Crohn’s

Approximately two-thirds of patients with Crohn’s disease who initially responded to anti-tumor necrosis factor therapy lost response by 3 years, with researchers suggesting that higher drug concentrations at induction may improve outcomes.

News
April 12, 2024
4 min read
Save

Amjevita leads Humira biosimilars in clinician comfort as rheumatologists remain wary

Only half of rheumatologists are “extremely comfortable” prescribing the Humira biosimilar Amjevita, while just 16% can say the same for all other adalimumab biosimilars combined, according to a market analysis from Spherix Global Insights.

News
February 27, 2024
1 min watch
Save

VIDEO: ‘So much’ placebo power can be harnessed to treat rheumatology patients

In this Healio video exclusive, Leonard Calabrese, DO, chief medical editor of Healio Rheumatology, discussed the top items from the February issue, including an exploration of how the placebo effect can be applied in rheumatology.

News
February 26, 2024
2 min read
Save

FDA approves Simlandi as third interchangeable Humira biosimilar

The FDA has approved Simlandi as the third interchangeable biosimilar to Humira following a rejection in April 2023 stemming from issues at the developer’s manufacturing facility.

View more